Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 18;12:975255. doi: 10.3389/fonc.2022.975255

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Song, Chi, Peng, Song, Cui, Zhu, Chen, Wu, Liu, Dong, Wang, Xu, Yu and Song

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Analysis of TME and immunotherapy among the high- and low-risk groups with SKCM patients. (A) Heatmap for immune infiltration based on QUANTISEQ, TIMER, CIBERSORT-ABS, CIBERSORT, XCELL, MCP-counter, and EPIC algorithms among high- and low-risk groups. (B, C) Based on the ssGSEA algorithm, the box plots illustrated the variation in immune cell infiltration and immune function among the low- and high-risk groups of SKCM patients. (D) Comparison of the immune, stromal and ESTIMATE scores between the low- and high-risk groups, respectively. (E, F, H) The distribution of IPS in the high-risk and low-risk groups in TCGA dataset. (I) The TIDE score between two risk subgroups. (G) SubMap analysis manifested that the low-risk group was more sensitive to the anti-PD-1 therapy. (*P < 0.05, **P < 0.01, ***P < 0.001 and ns = not significant).